HC Wainwright's Q4 Earnings Forecast for OmniAb

OmniAb, Inc. (NASDAQ:OABI - Free Report) has recently been the subject of analysis from research firm HC Wainwright. On March 19th, the firm provided their estimates for the company’s earnings per share (EPS) for the fourth quarter of 2025.

According to HC Wainwright analyst J. Pantginis, OmniAb is expected to report an EPS of ($0.15) for the upcoming quarter. Currently, HC Wainwright maintains a "Buy" rating on the stock, alongside a target price set at $11.00. The consensus among analysts for OmniAb's entire fiscal year earnings stands at ($0.61) per share. Additionally, HC Wainwright has projected that the company will have an EPS of ($0.29) for FY2029.

Market Response and Share Performance

On the market front, OmniAb's shares opened at $2.27 on Friday, reflecting a significant drop of 10.6% recently. The company boasts a market capitalization of approximately $320.56 million and carries a price-to-earnings (PE) ratio of -3.66. The stock has shown volatility, with a 50-day simple moving average of $3.36 and a longer 200-day average of $3.78. Over the past year, OmniAb's stocks ranged from a low of $2.23 to a high of $5.72.

Recent Earnings Report

OmniAb presented its quarterly earnings results on March 18th, reporting an EPS of ($0.12) for the quarter. This result was slightly better than the consensus estimate of ($0.13), with a small positive variance of $0.01. The company experienced a substantial negative net margin of 308.78% and a return on equity of -20.97%. Revenue for the quarter was reported at $10.80 million, surpassing analyst expectations of $10.13 million. A year prior, OmniAb posted an EPS of ($0.14).

Investors and Institutional Holdings

Recently, several large investors have adjusted their positions in OmniAb. For instance, HSBC Holdings PLC has acquired a new stake worth $38,000, while Choreo LLC and Rangeley Capital LLC have also entered into new positions valued at approximately $41,000 each. KLP Kapitalforvaltning AS and Walleye Capital LLC made similar moves in the fourth quarter, with holdings reaching $49,000 and $61,000 respectively. Institutional investors currently hold around 72.08% of the company's stock.

Insider Transactions

In other news concerning insider activity, CFO Kurt A. Gustafson sold 15,526 shares on January 21st at an average price of $3.24, totaling approximately $50,304.24. Following this transaction, he holds 212,720 shares valued at around $689,212.80, reflecting a 6.80% decrease in his stake. CEO Matthew W. Foehr also sold 13,964 shares on February 18th at an average price of $3.68, reaping about $51,387.52 from the sale. He now possesses roughly 3,798,682 shares valued at about $13,979,149.76, a minor decrease of 0.37%. In the past quarter, insiders have sold a total of 112,260 shares worth $376,601, and company insiders now own around 8.60% of the company’s stock.

About OmniAb

OmniAb, Inc. operates in the biotechnology sector, focusing on therapeutic antibody discovery technologies within the United States. The company specializes in creating and screening a diverse range of antibody repertoires to identify optimal antibodies suited for their partners' drug development initiatives.

OmniAb, Earnings, Analyst